Fresenius Kabi Issues Voluntary Recall of Sodium Acetate Injection, USP Due to the Presence of Particulate Matter

Date: 03/07/2022

Product Type: Drugs, Impurity

Company Announcement Date: March 07, 2022

FDA Publish Date:  March 07, 2022

Product Type:  Drugs

Reason for Announcement: Due to the presence of particulate matter found in reserve and/or stability sample vials

Company Name: Fresenius Kabi, USA

Brand Name: Fresenius Kabi, USA

Product Description: Sodium Acetate Injection, USP, 400 mEq/100 mL (4 mEq/mL), 100 mL fill in a 100 mL vial

USA-FDA Link:   https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/fresenius-kabi-issues-voluntary-recall-sodium-acetate-injection-usp-due-presence-particulate-matter